Pharmacogenetics of Paraoxonase Activity: Elucidating the Role of High-density Lipoprotein in Disease

Overview

Journal Pharmacogenomics

Specialties Genetics
Pharmacology

Date 2013 Sep 13

PMID 24024900

Citations 16

Authors

Daniel Seung Kim

Judit Marsillach

Clement E Furlong

Gail P Jarvik

Affiliations

Soon will be listed here.

Abstract

PON1 is a key component of high-density lipoproteins (HDLs) and is at least partially responsible for HDL's antioxidant/atheroprotective properties. PON1 is also associated with numerous human diseases, including cardiovascular disease, Parkinson's disease and cancer. In addition, PON1 metabolizes a broad variety of substrates, including toxic organophosphorous compounds, statin adducts, glucocorticoids, the likely atherogenic L-homocysteine thiolactone and the quorum-sensing factor of Pseudomonas aeruginosa. Numerous cardiovascular and antidiabetic pharmacologic agents, dietary macronutrients, lifestyle factors and antioxidant supplements affect PON1 expression and enzyme activity levels. Owing to the importance of PON1 to HDL function and its individual association with diverse human diseases, pharmacogenomic interactions between PON1 and the various factors that alter its expression and activity may represent an important therapeutic target for future investigation.

Citing Articles

Modulatory Effect of Lifestyle-Related, Environmental and Genetic Factors on Paraoxonase-1 Activity: A Review.

Kunachowicz D, Sciskalska M, Kepinska M Int J Environ Res Public Health. 2023; 20(4).

PMID: 36833509 PMC: 9957543. DOI: 10.3390/ijerph20042813.

A Novel Pathway Phenotype of Temporal Lobe Epilepsy and Comorbid Psychiatric Disorders: Results of Precision Nomothetic Medicine.

Maes M, Barbosa D, Almulla A, Kanchanatawan B Antioxidants (Basel). 2022; 11(5).

PMID: 35624666 PMC: 9137678. DOI: 10.3390/antiox11050803.

Human carboxylesterases and fluorescent probes to image their activity in live cells.

Singh A, Gao M, Beck M RSC Med Chem. 2021; 12(7):1142-1153.

PMID: 34355180 PMC: 8292992. DOI: 10.1039/d1md00073j.

Genotype and phenotype of salt-stimulated paraoxonase 1 (PON1) is associated with atherogenic indices in type 2 diabetes.

Qujeq D, Mahrooz A, Alizadeh A, Masoumi P, Annemohammadzadeh S, Boorank R J Diabetes Metab Disord. 2018; 17(1):1-10.

PMID: 30288380 PMC: 6154515. DOI: 10.1007/s40200-018-0332-z.

A role for plant science in underpinning the objective of global nutritional security?.

Martin C Ann Bot. 2018; 122(4):541-553.

PMID: 29982346 PMC: 6153469. DOI: 10.1093/aob/mcy118.

References

Ozer E, Pezzulo A, Shih D, Chun C, Furlong C, Lusis A . Human and murine paraoxonase 1 are host modulators of Pseudomonas aeruginosa quorum-sensing. FEMS Microbiol Lett. 2005; 253(1):29-37. DOI: 10.1016/j.femsle.2005.09.023. View

Eckerson H, Wyte C, La Du B . The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet. 1983; 35(6):1126-38. PMC: 1685985. View

Rainwater D, Mahaney M, Wang X, Rogers J, Cox L, VandeBerg J . Determinants of variation in serum paraoxonase enzyme activity in baboons. J Lipid Res. 2005; 46(7):1450-6. DOI: 10.1194/jlr.M400473-JLR200. View

Kontush A, Chantepie S, Chapman M . Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol. 2003; 23(10):1881-8. DOI: 10.1161/01.ATV.0000091338.93223.E8. View

Fang D, Fan C, Ji Q, Qi B, Li J, Wang L . Differential effects of paraoxonase 1 (PON1) polymorphisms on cancer risk: evidence from 25 published studies. Mol Biol Rep. 2012; 39(6):6801-9. DOI: 10.1007/s11033-012-1505-3. View

Li W, Costa L, Furlong C . Serum paraoxonase status: a major factor in determining resistance to organophosphates. J Toxicol Environ Health. 1993; 40(2-3):337-46. DOI: 10.1080/15287399309531798. View

Furlong C, Suzuki S, Stevens R, Marsillach J, Richter R, Jarvik G . Human PON1, a biomarker of risk of disease and exposure. Chem Biol Interact. 2010; 187(1-3):355-61. PMC: 3035622. DOI: 10.1016/j.cbi.2010.03.033. View

Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R . Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol. 2004; 11(5):412-9. DOI: 10.1038/nsmb767. View

Costa L, McDonald B, Murphy S, Omenn G, Richter R, Motulsky A . Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. Toxicol Appl Pharmacol. 1990; 103(1):66-76. DOI: 10.1016/0041-008x(90)90263-t. View

10.

Cole T, Walter B, Shih D, Tward A, Lusis A, Timchalk C . Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. Pharmacogenet Genomics. 2005; 15(8):589-98. DOI: 10.1097/01.fpc.0000167327.08034.d2. View

11.

Kaplan M, Hayek T, Raz A, Coleman R, Dornfeld L, Vaya J . Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. J Nutr. 2001; 131(8):2082-9. DOI: 10.1093/jn/131.8.2082. View

12.

McElveen J, Mackness M, Colley C, Peard T, Warner S, Walker C . Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem. 1986; 32(4):671-3. View

13.

Mirdamadi H, Sztanek F, Derdak Z, Seres I, Harangi M, Paragh G . The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. Br J Clin Pharmacol. 2008; 66(3):366-74. PMC: 2526235. DOI: 10.1111/j.1365-2125.2008.03213.x. View

14.

Jaichander P, Selvarajan K, Garelnabi M, Parthasarathy S . Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J Lipid Res. 2008; 49(10):2142-8. PMC: 2533409. DOI: 10.1194/jlr.M800082-JLR200. View

15.

Noll C, Messaoudi S, Milliez P, Samuel J, Delcayre C, Janel N . Eplerenone administration has beneficial effect on hepatic paraoxonase 1 activity in diabetic mice. Atherosclerosis. 2009; 208(1):26-7. DOI: 10.1016/j.atherosclerosis.2009.06.038. View

16.

Hong S, Zhao S, Wu Z . Probucol up-regulates paraoxonase 1 expression in hepatocytes of hypercholesterolemic rabbits. J Cardiovasc Pharmacol. 2006; 47(1):77-81. DOI: 10.1097/01.fjc.0000194687.19335.59. View

17.

Richter R, Jarvik G, Furlong C . Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. Circ Cardiovasc Genet. 2009; 1(2):147-52. PMC: 3035628. DOI: 10.1161/CIRCGENETICS.108.811638. View

18.

HUMBERT R, Adler D, Disteche C, Hassett C, Omiecinski C, Furlong C . The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993; 3(1):73-6. DOI: 10.1038/ng0193-73. View

19.

Jakubowski H . Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem. 2000; 275(6):3957-62. DOI: 10.1074/jbc.275.6.3957. View

20.

Liu Y, Yang J, Zheng J, Liu D, Liu T, Wang J . Paraoxonase 1 polymorphisms L55M and Q192R were not risk factors for Parkinson's disease: a HuGE review and meta-analysis. Gene. 2012; 501(2):188-92. DOI: 10.1016/j.gene.2012.03.067. View